Improve Efficiency, Stability and Applications of Adoptive T Cell Therapy
Strengthen efficacy and safety evidence using relevant preclinical models and translational data.
Offer overview
What this offer helps you achieve
Strengthen efficacy and safety evidence using relevant preclinical models and translational data.
Scientific and technical scope
Our technology enhances CAR-T cell therapy for solid tumors by overcoming their immunosuppressive environment. SOCS1 inactivation in CD4+ and CD8+ T cells boosts intratumor accumulation, proliferation, survival, and functionality, promoting tumor rejection. This results in more effective, durable CAR-T therapies and enables the production of functional off-the-shelf allogenic cells.
Capabilities mobilised
Therapeutic areasValidation using preclinical modelsBiomarkers
Application fields
Oncology
Discuss this offer
Could this capability strengthen your R&D programme?
Present your scientific, technical or clinical need and identify the most relevant route to collaboration.
Continue exploring
Related expertise for your programme
Offers selected through shared capabilities, application fields or institute expertise.
